TICKERNERD
Menu
PLURPLURHealthcare · Biotechnology

PLUR Stock Forecast: Pluri, Inc. Price Predictions for 2026-2027

Last close, 12 Aug 2026
$1.65
−5.71% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 9 of 100 as at 12 Aug 2026 — in the weakest quartile.

Market cap
$19.9M
Ticker Nerd rank
9 / 100
Median analyst target
—
Analysts covering
1
Total return, dividends reinvested
1W
−5.2%
1M
−4.1%
YTD
−44.8%
1Y
−65.2%
From 52W high
−71.0%
From 52W low
+6.5%
$1.55
$5.68
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PLUR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pluri, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Aug 2026
9 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
89
Accruals
62
Growth
48
Revisions
25
Volatility
14
Issuance
10
Momentum
9
Quality
8
Value
7

Size (89): Smaller than most of the companies we track.

Value (7): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PLUR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PLUR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26PLUR

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 June 2025Alliance Global PartnersInitiatesBuy$12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PLUR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PLUR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Pluri, Inc. (PLUR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.5×

Cheaper than 80% of US stocks

Price / sales
18.2×

Cheaper than 10% of US stocks

Price / book
−1.4×

Cheaper than 94% of US stocks

EV / EBITDA
−1.9×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
−60.9%

Higher than 4% of US stocks

Earnings growth (YoY)
—
Gross margin
33.5%

Higher than 40% of US stocks

Operating margin
−3913.8%

Higher than 3% of US stocks

Net margin
49.0%

Higher than 96% of US stocks

Returns & dividend
Return on equity
2610.8%

Higher than 99% of US stocks

Return on assets
−51.2%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PLUR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PLURPluri, Inc.$19.9M
9
NRSNNeurosense Therapeutics Ltd.$17.7M
3
NCELNewCelX Ltd.$17.8M
17
CYCNCyclerion Therapeutics, Inc.$18.4M
32
TVRDTvardi Therapeutics, Inc.$16.6M
25
HOWLWerewolf Therapeutics, Inc.$18.5M
53
LPCNLipocine, Inc.$16.5M
38

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pluri, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PLUR news & analysis

Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK

GlobeNewsWire · 28 July 2026positive

Pluri's consumer-health subsidiary, Cellav, completed regulatory registration in the UK for its regenerative aesthetics product Regenativo+, paving the way for a commercial launch in a market estimated at roughly $900 million annually.

Why it matters — This milestone advances Pluri's commercialization strategy by opening a significant new market and laying the groundwork for broader international expansion of its regenerative aesthetics portfolio.

FAQ

Frequently asked questions about PLUR stock

Is PLUR stock a buy right now?

Of the 1 analysts covering Pluri, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pluri, Inc. 9 out of 100 across roughly 4,600 US stocks as at 12 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PLUR?

As at 12 Aug 2026, Pluri, Inc. ranks 9 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).

What is the PLUR stock forecast for 2030?

No analyst covering Pluri, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLUR are extrapolating price history, which says nothing about the business.

How has PLUR stock performed over the past year?

Pluri, Inc. returned -65.2% over the 12 months to 12 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pluri, Inc. do?

Pluri Inc. is a biotechnology company focusing on cell-based therapeutics and technology-driven innovations to address complex medical conditions.

What is the latest news on PLUR?

The most recent item we track (GlobeNewsWire, 28 July 2026): "Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK". Pluri's consumer-health subsidiary, Cellav, completed regulatory registration in the UK for its regenerative aesthetics product Regenativo+, paving the way for a commercial launch in a market estimated at roughly $900 million annually.

Company

About Pluri, Inc.

Pluri Inc. is a biotechnology company focusing on cell-based therapeutics and technology-driven innovations to address complex medical conditions. The primary function of Pluri is to harness advanced cell-production technologies to develop a wide array of potential therapies that may transform treatment modalities across various sectors. Pluri's expertise lies in using proprietary 3D cell culture platforms to cultivate placental cells, which are then utilized in regenerative medicine applications. These applications have significant implications for industries including orthopedics, cardiovascular health, and autoimmune diseases. The company's innovative approach seeks to provide scalable and sustainable solutions in tissue engineering and organ regeneration, aiming to meet unmet medical needs globally. Pluri Inc.'s commitment to research and development in biotechnology underlines its pivotal role in pioneering new therapeutic strategies, making it a significant entity within the healthcare and life sciences sectors. Established to impact global health, Pluri continues to explore a dynamic intersection between cutting-edge technology and medical sciences, contributing to a potential shift in how chronic illnesses and acute health challenges are managed.

CEO Mr. Yaacov Yanay · 127 employees · Israel · https://www.pluri-biotech.com